GenMark Diagnostics (GNMK) Reports In-Line Q4 EPS

GenMark Diagnostics (NASDAQ: GNMK) reported Q4 EPS of ($0.26), in-line with the analyst estimate of ($0.26). Revenue for the quarter came in at $16 million versus the consensus estimate of $15.64 million.

GUIDANCE:

GenMark Diagnostics sees FY 2018 revenue of $68-72 million, versus the consensus of $69.5 million.

For earnings history and earnings-related data on GenMark Diagnostics (GNMK) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• First Watch (FWRG) PT Lowered to $15 at DA Davidson, Buy Rating Maintained
• Cuprina to buy seven-clinic Singapore healthcare group for S$4M